id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S8086 R24723 |
Aydin (Phenytoin) (Controls exposed to Lamotrigine, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
3.67 [0.05;274.53] C excluded (control group) |
1/1 2/7 | 3 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8079 R24662 |
Aydin (Phenytoin) (Controls unexposed, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 13.67 [0.19;964.02] C | 1/1 2/22 | 3 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5922 R15036 |
Artama (Phenytoin) (Controls exposed to Lamotrigine, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.13 [0.01;2.20] C excluded (control group) |
0/21 24/154 | 24 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S305 R14804 |
Artama (Phenytoin) (Controls unexposed, disease free), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
0.31 [0.02;5.20] C excluded (control group) |
0/21 49,612/689,482 | 49,612 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5914 R14940 |
Artama (Phenytoin) (Controls unexposed, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: No | 0.25 [0.01;4.13] C | 0/21 152/1,708 | 152 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6174 R16247 |
Viinikainen (Phenytoin) (Controls unexposed, disease free) a, 2006 | Admission to a neonatal unit | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No | 4.20 [0.17;103.11] C | 0/2 1,822/24,778 | 1,822 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S341 R18447 |
D'Souza (Phenytoin) (Controls unexposed, disease free), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
9.00 [0.35;229.68] C excluded (control group) |
1/22 0/62 | 1 | 22 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6690 R18749 |
D'Souza (Phenytoin) (Controls unexposed, sick), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.10 [0.04;30.00] C | 1/22 0/8 | 1 | 22 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.37 [0.26;7.15] | 1,978 | 46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenytoin) (Controls unexposed, sick; 2: Phenytoin) (Controls unexposed, sick; 3: Phenytoin) (Controls unexposed, disease free) ; 4: Phenytoin) (Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 341, 5922, 305, 8086